{"id":1008635,"date":"2026-10-08T11:23:41","date_gmt":"2026-10-08T15:23:41","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/imunon-to-participate-in-upcoming-investor-conferences\/"},"modified":"2026-10-08T11:23:41","modified_gmt":"2026-10-08T15:23:41","slug":"imunon-to-participate-in-upcoming-investor-conferences","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/imunon-to-participate-in-upcoming-investor-conferences\/","title":{"rendered":"IMUNON to Participate in Upcoming Investor Conferences"},"content":{"rendered":"<div class=\"mw_release\">\n<p align=\"justify\">\n        <b>LAWRENCEVILLE, N.J., Oct.  08, 2026  (GLOBE NEWSWIRE) &#8212; <\/b>IMUNON, Inc. (Nasdaq: IMNN), a clinical-stage biotechnology company developing DNA-mediated immunotherapies, today announced that Stacy Lindborg, Ph.D., President and Chief Executive Officer, will participate in the following October 2026 investor conferences.<\/p>\n<p>\n        <b><br \/>\n          <u>Maxim Growth Summit 2026<\/u><br \/>\n        <\/b><br \/>\n        <br \/>\n        <b>Date:<\/b>\u00a0October 12 &#8211; 14, 2026<br \/><b>Location:<\/b>\u00a0Hard Rock Hotel, New York, NY<br \/><b>Presentation:<\/b> Oncology Panel, October 14, 2026, at 9:00 a.m. ET<\/p>\n<p>For more information and a complete agenda of the Maxim Growth Summit, please visit\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=0K1TuTJ6w4lhNyHGLNN4HekjRO1QPsL98mt3QMIW32prI1lUJLRg4AiMiRvdyWqengpLQB6wLToGvIt8VGWLWCUMLzuWleQ-iNQ49UwPLQb_l6A-jSgSrqoX5xwNm4qxVhcZtg35qQCkHgWh08x2Ebrh78-9NE35tbrvcSjQKz0=\" rel=\"nofollow\" target=\"_blank\">https:\/\/www.maximgrp.com\/2026-growth-summit<\/a>.<\/p>\n<p>\n        <b><br \/>\n          <u>2026 ThinkEquity Conference<\/u><br \/>\n        <\/b><br \/>\n        <br \/>\n        <b>Date:<\/b>\u00a0October 15, 2026<br \/><b>Location:<\/b>\u00a0Mandarin Oriental Hotel, New York, NY<br \/><b>Presentation:<\/b> 1:30 p.m. ET in the Boardroom<\/p>\n<p>For more information and a complete agenda of the ThinkEquity Conference, please visit\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=0K1TuTJ6w4lhNyHGLNN4HRm4s1G1zfW9rKEqZV925nGoyoUIr1Sv_sVc_sGvyNC94nkIFNbRG3kPAsYtCz5lj6LpzuxQDVlMb3YKym5XiDxnWcd2PxFLHabfXcCaR_GU1dwFfE9rjCUMMUo8jTZzPQ==\" rel=\"nofollow\" target=\"_blank\">https:\/\/www.think-equity.com\/thinkequity-conference<\/a>.<\/p>\n<p align=\"justify\">The Company will host 1&#215;1 meetings throughout the conferences. For more information or to schedule a meeting, please contact Maxim Group or ThinkEquity conference representatives or email <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=if7xRx03ysshN14ZnlD_FlQKlpg7I7di37vj5gjSkFGjo5j2yvdN0yDxIedVxvWdzR_jTBB-b1ZCoew0Xqz1-w==\" rel=\"nofollow\" target=\"_blank\">imunon@kcsa.com<\/a>.<\/p>\n<p align=\"justify\">\n        <b>About IMUNON<\/b>\n      <\/p>\n<p align=\"justify\">IMUNON is a clinical-stage biotechnology company focused on advancing a portfolio of innovative treatments that harness the body\u2019s natural mechanisms to generate safe, effective and durable responses across a broad array of human diseases, constituting a differentiating approach from conventional therapies. IMUNON is developing its non-viral DNA-based gene therapy technology across its modalities. The first modality, TheraPlas<sup>\u00ae<\/sup>, is developed for the gene-based delivery of cytokines and other therapeutic proteins in the treatment of solid tumors where an immunological approach is deemed promising. The second modality, PlaCCine<sup>\u00ae<\/sup>, is developed for the gene delivery of viral antigens that can elicit a strong immunological response.<\/p>\n<p align=\"justify\">The Company\u2019s lead clinical program, IMNN-001, is a DNA-based immunotherapy being developed for the localized treatment of advanced ovarian cancer. IMNN-001 has been evaluated in multiple clinical trials including one Phase 2 clinical trial (OVATION 2) and is currently being studied in the ongoing Phase 3 clinical trial (OVATION 3). IMNN-001 works by instructing the body to produce safe and durable levels of powerful cancer-fighting molecules, such as interleukin-12 and interferon gamma, at the tumor site. Additionally, the Company has completed dosing in a first-in-human study of its COVID-19 booster vaccine (IMNN-101). The Company will continue to leverage these modalities and to advance, either directly or through partnership, the technological frontier of plasmid DNA to better serve patients with difficult-to-treat conditions. For more information, please visit\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=fv0SKQCXSQG9mPngCFVv6Shq2sw_lG-pvLzBvKPHSDKfu-wyRn1wVlbmxXL42zLewzBsYVe-mnKphFBSED94LFWs69b7aDo8jAan9F3auwycBQ4HmD9MDldikXJgCJuLt2zvZhKOY8bC98Mzyq1LSQctwx78_kaj_udXIcE08QD27r4u9hION_Rx-0m71yqw8RV42MMFEqQV2CePUP5V-yQbG0YzcNVSu81Tsbx1Ie0=\" rel=\"nofollow\" target=\"_blank\"><b>www.imunon.com<\/b><\/a>.<\/p>\n<p>\n        <b>Investor Contact:<\/b><br \/>\n        <br \/>Valter Pinto<br \/>KCSA Strategic Communications<br \/>212-896-1254<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=if7xRx03ysshN14ZnlD_FtPs1UuR5_VbW5-T3PE3ZNNAJmaxchCHCEpMHnd6C7vNqRkWJMoL-UgEwvXrVWZq--OvHO7ureeqYraLy853cIjYNQhZRsUXXsFni8F9vWRmBvtsnIG7TQzHeLPGd3RPmLRHJ6Hi84bLW0NcaLXDkAXZAfbwtfXVB2L7GtsZR7NGF5Xo5cPJRYaVFzsnk9DCbZs00vAL2XyX2OHhBsDLJ7dcaiPcBEPiCZf6ZNuPbE4pfX_CfwyT9ZqSXyEVUWnROg==\" rel=\"nofollow\" target=\"_blank\">imunon@kcsa.com<\/a><\/p>\n<p>      <img decoding=\"async\" alt=\"\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTg0MjAyNCM3ODg1NjQ4IzUwMDA0OTc3Ng==\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" alt=\"\" src=\"https:\/\/ml.globenewswire.com\/media\/MDI5NGRlN2ItZTY5Zi00OGU1LWEwOWUtOGRjYTQ4MTEyZTE5LTUwMDA0OTc3Ni0yMDI2LTEwLTA4LWVu\/tiny\/Imunon-Inc-.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>LAWRENCEVILLE, N.J., Oct. 08, 2026 (GLOBE NEWSWIRE) &#8212; IMUNON, Inc. (Nasdaq: IMNN), a clinical-stage biotechnology company developing DNA-mediated immunotherapies, today announced that Stacy Lindborg, Ph.D., President and Chief Executive Officer, will participate in the following October 2026 investor conferences. Maxim Growth Summit 2026 Date:\u00a0October 12 &#8211; 14, 2026Location:\u00a0Hard Rock Hotel, New York, NYPresentation: Oncology Panel, October 14, 2026, at 9:00 a.m. ET For more information and a complete agenda of the Maxim Growth Summit, please visit\u00a0https:\/\/www.maximgrp.com\/2026-growth-summit. 2026 ThinkEquity Conference Date:\u00a0October 15, 2026Location:\u00a0Mandarin Oriental Hotel, New York, NYPresentation: 1:30 p.m. ET in the Boardroom For more information and a complete agenda of the ThinkEquity Conference, please visit\u00a0https:\/\/www.think-equity.com\/thinkequity-conference. The Company will host 1&#215;1 meetings throughout the conferences. For more information or to &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/imunon-to-participate-in-upcoming-investor-conferences\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;IMUNON to Participate in Upcoming Investor Conferences&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-1008635","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v28.6 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>IMUNON to Participate in Upcoming Investor Conferences - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/imunon-to-participate-in-upcoming-investor-conferences\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"IMUNON to Participate in Upcoming Investor Conferences - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"LAWRENCEVILLE, N.J., Oct. 08, 2026 (GLOBE NEWSWIRE) &#8212; IMUNON, Inc. (Nasdaq: IMNN), a clinical-stage biotechnology company developing DNA-mediated immunotherapies, today announced that Stacy Lindborg, Ph.D., President and Chief Executive Officer, will participate in the following October 2026 investor conferences. Maxim Growth Summit 2026 Date:\u00a0October 12 &#8211; 14, 2026Location:\u00a0Hard Rock Hotel, New York, NYPresentation: Oncology Panel, October 14, 2026, at 9:00 a.m. ET For more information and a complete agenda of the Maxim Growth Summit, please visit\u00a0https:\/\/www.maximgrp.com\/2026-growth-summit. 2026 ThinkEquity Conference Date:\u00a0October 15, 2026Location:\u00a0Mandarin Oriental Hotel, New York, NYPresentation: 1:30 p.m. ET in the Boardroom For more information and a complete agenda of the ThinkEquity Conference, please visit\u00a0https:\/\/www.think-equity.com\/thinkequity-conference. The Company will host 1&#215;1 meetings throughout the conferences. For more information or to &hellip; Continue reading &quot;IMUNON to Participate in Upcoming Investor Conferences&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/imunon-to-participate-in-upcoming-investor-conferences\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2026-10-08T15:23:41+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTg0MjAyNCM3ODg1NjQ4IzUwMDA0OTc3Ng==\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/imunon-to-participate-in-upcoming-investor-conferences\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/imunon-to-participate-in-upcoming-investor-conferences\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"IMUNON to Participate in Upcoming Investor Conferences\",\"datePublished\":\"2026-10-08T15:23:41+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/imunon-to-participate-in-upcoming-investor-conferences\\\/\"},\"wordCount\":393,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/imunon-to-participate-in-upcoming-investor-conferences\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTg0MjAyNCM3ODg1NjQ4IzUwMDA0OTc3Ng==\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/imunon-to-participate-in-upcoming-investor-conferences\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/imunon-to-participate-in-upcoming-investor-conferences\\\/\",\"name\":\"IMUNON to Participate in Upcoming Investor Conferences - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/imunon-to-participate-in-upcoming-investor-conferences\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/imunon-to-participate-in-upcoming-investor-conferences\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTg0MjAyNCM3ODg1NjQ4IzUwMDA0OTc3Ng==\",\"datePublished\":\"2026-10-08T15:23:41+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/imunon-to-participate-in-upcoming-investor-conferences\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/imunon-to-participate-in-upcoming-investor-conferences\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/imunon-to-participate-in-upcoming-investor-conferences\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTg0MjAyNCM3ODg1NjQ4IzUwMDA0OTc3Ng==\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTg0MjAyNCM3ODg1NjQ4IzUwMDA0OTc3Ng==\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/imunon-to-participate-in-upcoming-investor-conferences\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"IMUNON to Participate in Upcoming Investor Conferences\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"IMUNON to Participate in Upcoming Investor Conferences - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/imunon-to-participate-in-upcoming-investor-conferences\/","og_locale":"en_US","og_type":"article","og_title":"IMUNON to Participate in Upcoming Investor Conferences - Market Newsdesk","og_description":"LAWRENCEVILLE, N.J., Oct. 08, 2026 (GLOBE NEWSWIRE) &#8212; IMUNON, Inc. (Nasdaq: IMNN), a clinical-stage biotechnology company developing DNA-mediated immunotherapies, today announced that Stacy Lindborg, Ph.D., President and Chief Executive Officer, will participate in the following October 2026 investor conferences. Maxim Growth Summit 2026 Date:\u00a0October 12 &#8211; 14, 2026Location:\u00a0Hard Rock Hotel, New York, NYPresentation: Oncology Panel, October 14, 2026, at 9:00 a.m. ET For more information and a complete agenda of the Maxim Growth Summit, please visit\u00a0https:\/\/www.maximgrp.com\/2026-growth-summit. 2026 ThinkEquity Conference Date:\u00a0October 15, 2026Location:\u00a0Mandarin Oriental Hotel, New York, NYPresentation: 1:30 p.m. ET in the Boardroom For more information and a complete agenda of the ThinkEquity Conference, please visit\u00a0https:\/\/www.think-equity.com\/thinkequity-conference. The Company will host 1&#215;1 meetings throughout the conferences. For more information or to &hellip; Continue reading \"IMUNON to Participate in Upcoming Investor Conferences\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/imunon-to-participate-in-upcoming-investor-conferences\/","og_site_name":"Market Newsdesk","article_published_time":"2026-10-08T15:23:41+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTg0MjAyNCM3ODg1NjQ4IzUwMDA0OTc3Ng==","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/imunon-to-participate-in-upcoming-investor-conferences\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/imunon-to-participate-in-upcoming-investor-conferences\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"IMUNON to Participate in Upcoming Investor Conferences","datePublished":"2026-10-08T15:23:41+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/imunon-to-participate-in-upcoming-investor-conferences\/"},"wordCount":393,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/imunon-to-participate-in-upcoming-investor-conferences\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTg0MjAyNCM3ODg1NjQ4IzUwMDA0OTc3Ng==","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/imunon-to-participate-in-upcoming-investor-conferences\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/imunon-to-participate-in-upcoming-investor-conferences\/","name":"IMUNON to Participate in Upcoming Investor Conferences - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/imunon-to-participate-in-upcoming-investor-conferences\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/imunon-to-participate-in-upcoming-investor-conferences\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTg0MjAyNCM3ODg1NjQ4IzUwMDA0OTc3Ng==","datePublished":"2026-10-08T15:23:41+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/imunon-to-participate-in-upcoming-investor-conferences\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/imunon-to-participate-in-upcoming-investor-conferences\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/imunon-to-participate-in-upcoming-investor-conferences\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTg0MjAyNCM3ODg1NjQ4IzUwMDA0OTc3Ng==","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTg0MjAyNCM3ODg1NjQ4IzUwMDA0OTc3Ng=="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/imunon-to-participate-in-upcoming-investor-conferences\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"IMUNON to Participate in Upcoming Investor Conferences"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/1008635","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=1008635"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/1008635\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=1008635"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=1008635"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=1008635"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}